Acute promyelocytic leukemia (APL): remaining challenges towards a cure for all

Maximilian Stahl, Martin S. Tallman*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

50 Scopus citations


The application of all-trans retinoic acid (ATRA) and arsenic trioxide (ATO) has revolutionized the treatment of acute promyelocytic leukemia (APL). More than 80–90% of patients are expected to be cured with a combination of ATRA, ATO and/or chemotherapy. In this review, we focus on the remaining obstacles to a cure for all patients with APL. We review the issue of early death and coagulopathy and discuss the particular challenges in the care of patients with high-risk APL and patients with relapsed APL. We also give recommendations and highlight ongoing efforts to improve the persistently high early death rate and the outcomes of high risk and relapsed APL patients.

Original languageEnglish (US)
Pages (from-to)3107-3115
Number of pages9
JournalLeukemia and Lymphoma
Issue number13
StatePublished - Nov 10 2019


  • APL
  • ATRA
  • cure

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research


Dive into the research topics of 'Acute promyelocytic leukemia (APL): remaining challenges towards a cure for all'. Together they form a unique fingerprint.

Cite this